Clinical and Economic Outcomes of Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections Documented or at Risk of Methicillin-Resistant S. Aureus

Trial Profile

Clinical and Economic Outcomes of Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections Documented or at Risk of Methicillin-Resistant S. Aureus

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2016

At a glance

  • Drugs Ceftaroline fosamil (Primary) ; Vancomycin
  • Indications Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Oct 2016 Status changed from recruiting to completed.
    • 08 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
    • 27 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top